What is DTIL (DTIL) stock price today?

DTIL (DTIL) is currently trading at $7.00, up 1.6% today.

What is DTIL P/E ratio?

DTIL's P/E ratio is -1.97. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is DTIL return on equity (ROE)?

DTIL's return on equity (ROE) is -51.09%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is DTIL's market cap?

DTIL has a market capitalization of $89.80M.

NASDAQ · Biotechnology

DTIL (DTIL) Stock

$7.00 +1.60% NASDAQ: DTIL Healthcare

Valuation

Metric	Value
Price	$7.00
Market Cap	$89.80M
P/E Ratio	-1.97
P/B Ratio	1.00
P/S Ratio	2.04
EPS (TTM)	$-3.63
52-Week High	$9.36
52-Week Low	$3.53
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-51.09%
ROA	-30.52%
ROCE	-56.52%
Gross Margin	-152.94%
Operating Margin	-152.94%
Net Margin	-98.70%
Debt/Equity	0.37
Current Ratio	13.22

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$116.0M	$25.0M	$49.0M	$69.0M	$34.0M
Operating Profit	$-39.0M	$-62.0M	$-44.0M	$-26.0M	$-52.0M
Net Profit	$-31.0M	$-112.0M	$-61.0M	$7.0M	$-47.0M
EPS	$-15.60	$-38.10	$-15.96	$1.04	$-3.63
Op Margin	-34.1%	-248.3%	-89.8%	-38.1%	-152.2%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$211.0M	$238.0M	$160.0M	$136.0M	$154.0M
Total Liabilities	$120.0M	$178.0M	$141.0M	$80.0M	$62.0M
Cash	$144.0M	$190.0M	$117.0M	$86.0M	$111.0M
Borrowings	$9.0M	$25.0M	$31.0M	$30.0M	$29.0M

Latest News

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire · Jul 10, 2026 Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength? Zacks · Jul 8, 2026 Precision BioSciences Joins Russell 2000 Index MT Newswires · Jun 29, 2026 Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors Business Wire · Jun 29, 2026 Oppenheimer Initiates Precision BioSciences at Outperform MT Newswires · Jun 9, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-11.0M	$-46.0M	$-84.0M	$-58.0M	$-66.0M
Investing Cash Flow	$-12.0M	$-7.0M	$4.0M	$0	$-1.0M
Financing Cash Flow	$8.0M	$1.0M	$0	$0	$0
Net Cash Flow	$54.0M	$46.0M	$-73.0M	$-8.0M	$29.0M
Free Cash Flow	$-17.0M	$-49.0M	$-86.0M	$-59.0M	$-66.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-63.82%
Quick Ratio	14.02
Interest Coverage	-52.00
Return 1Y	86.07%
Return 3Y	-59.41%
Return 5Y	-97.39%

Ownership

Insiders Held6.44%

Institutions Held65.86%

Institutions Float Held70.39%

Institutional Holder	Shares	Report Date
Octagon Capital Advisors LP	2,236,732	2026-03-31
Aberdeen Group plc	2,230,178	2026-03-31
Empery Asset Management, LP	1,968,879	2026-03-31
Bleichroeder LP	1,662,500	2026-03-31
Boothbay Fund Management, LLC	1,066,050	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ABOS	$2.27	-0.66%	-1.17	$163.60M	0.00%
ALEC	$1.52	+0.33%	-1.58	$168.20M	0.00%
GOSSGossamer Bio, Inc.	$0.19	+38.24%	-0.17	$44.10M	0.00%
HOOKHOOKIPA Pharma Inc.	$1.15	+0.00%	-0.71	$14.40M	0.00%
HRTX	$0.51	+3.06%	-7.08	$96.80M	0.00%

About DTIL

DTIL is led by CEO Juli Blanche, employs 108 people, headquartered in US, publicly traded since 2019.

DTIL stock trades at $7.00 with a market capitalization of $89.80M. The stock is valued at a price-to-earnings (P/E) ratio of -1.97, price-to-book of 1.00, price-to-sales of 2.04. Over the past 52 weeks the stock has ranged between $3.53 and $9.36, and currently trades 25.2% below its 52-week high.

On profitability, DTIL generates a return on equity (ROE) of -51.09%, return on capital employed of -56.52%, an operating margin of -152.94%, a net profit margin of -98.70%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides